NUVB (Nuvation Bio) Beginning Cash Position: $125.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NUVB Nuvation Bio Inc NUVB
32 GF Score
Price $6.42
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio Beginning Cash Position?

Nuvation Bio NUVB +0.78% 32 Beginning Cash Position is $125.4 Mil as of Jun. 2026. GuruFocus rates NUVB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Nuvation Bio's Beginning Cash Position for the quarter that ended in Jun. 2026 was $125.4 Mil.

Nuvation Bio's quarterly Beginning Cash Position increased from Dec. 2025 ($98.9 Mil) to Mar. 2026 ($164.1 Mil) but then declined from Mar. 2026 ($164.1 Mil) to Jun. 2026 ($125.4 Mil).

Nuvation Bio's annual Beginning Cash Position declined from Dec. 2023 ($101.1 Mil) to Dec. 2024 ($42.6 Mil) and declined from Dec. 2024 ($42.6 Mil) to Dec. 2025 ($35.7 Mil).

Nuvation Bio Beginning Cash Position Related Terms

Nuvation Bio Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Nuvation Bio's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio Beginning Cash Position Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 29.75 132.42 101.10 42.65 35.72

Nuvation Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.98 247.97 98.90 164.09 125.39
NUVB
32GF Score
Nuvation Bio Inc NUVB
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvation Bio Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $125.4 Mil mean?
Nuvation Bio (NUVB) has a Beginning Cash Position of $125.4 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nuvation Bio and its competitors.
Is Nuvation Bio's Beginning Cash Position too high?
Nuvation Bio's current Beginning Cash Position is $125.4 Mil. Overall, Nuvation Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Beginning Cash Position compare to IOVA and SLS?
Nuvation Bio's Beginning Cash Position of $125.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current Beginning Cash Position is $125.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Beginning Cash Position of $125.4 Mil. The current Beginning Cash Position is $125.4 Mil. Nuvation Bio's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Beginning Cash Position is $125.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges 1E30:Germany
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
32GF Score

Get the complete analysis for NUVB

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.42
Price